ATHE
NASDAQAlterity Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.39-2.55 (-51.62%)
2026-07-162026-10-16
News · 26 weeks80-67%
2026-04-192026-10-11
Mix4190d
- SEC Filings30(73%)
- Other7(17%)
- Insider2(5%)
- Leadership1(2%)
- Analyst1(2%)
Latest news
25 items- PRAlterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceMELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to c
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement DisordersATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3 MELBOURNE, Australia and SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that additional analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) were presen
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form S-8 filed by Alterity Therapeutics LimitedS-8 - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- INSIDERDirector Marks Peter Ashley bought $23,810 worth of Ordinary shares (47,620 units at $0.50) (SEC Form 4)4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Stamler David Allen4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States. A link to the live and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations. About Alterity Therapeutics Limited Alterity Therapeutics is a clinic
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 20-F filed by Alterity Therapeutics Limited20-F - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
ATHE FAQ
6 questionsWhat does Alterity Therapeutics Limited do?
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.Where does ATHE stock trade?
Alterity Therapeutics Limited (ATHE) is listed on NASDAQ.What sector and industry is ATHE in?
Alterity Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATHE?
Alterity Therapeutics Limited has had 5 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $1200.00 price target on 2026-08-11. Recent price targets range from $400.00 to $1200.00.What companies are similar to ATHE?
Notable peers in the same industry include RUBY (Rubius Therapeutics Inc.), ACRS (Aclaris Therapeutics Inc.), ONTX (Onconova Therapeutics Inc.). Compare ATHE side-by-side with any of them on Quantisnow.How can I track ATHE on Quantisnow?
Quantisnow aggregates Alterity Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATHE to receive live email and push alerts on every new disclosure.